The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 16, 2019

Filed:

Jun. 03, 2016
Applicants:

Lead Pharma Holding B.v., Nijmegen, NL;

Sanofi, Paris, FR;

Assignees:

LEAD PHARMA HOLDING B.V., Nijmegen, NL;

SANOFI, Paris, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 31/167 (2006.01); A61K 31/4164 (2006.01); A61K 31/415 (2006.01); A61K 31/426 (2006.01); A61K 31/4439 (2006.01); A61K 31/381 (2006.01); A61K 31/4436 (2006.01); A61K 31/4402 (2006.01); A61K 31/4245 (2006.01); A61K 31/421 (2006.01); A61K 31/4196 (2006.01); A61P 37/00 (2006.01); A61P 29/00 (2006.01); C07D 317/32 (2006.01); C07D 233/61 (2006.01); C07D 231/12 (2006.01); C07D 277/54 (2006.01); C07D 417/12 (2006.01); C07D 333/36 (2006.01); C07D 409/04 (2006.01); C07D 213/72 (2006.01); C07D 263/32 (2006.01); C07D 249/08 (2006.01); C07D 271/06 (2006.01); C07C 317/32 (2006.01); C07D 213/75 (2006.01); C07C 311/20 (2006.01); C07D 277/46 (2006.01); C07C 317/44 (2006.01);
U.S. Cl.
CPC ...
C07C 317/32 (2013.01); A61K 31/167 (2013.01); A61K 31/381 (2013.01); A61K 31/415 (2013.01); A61K 31/4164 (2013.01); A61K 31/4196 (2013.01); A61K 31/421 (2013.01); A61K 31/426 (2013.01); A61K 31/4245 (2013.01); A61K 31/4402 (2013.01); A61K 31/4436 (2013.01); A61K 31/4439 (2013.01); C07C 311/20 (2013.01); C07C 317/44 (2013.01); C07D 213/72 (2013.01); C07D 213/75 (2013.01); C07D 231/12 (2013.01); C07D 233/61 (2013.01); C07D 249/08 (2013.01); C07D 263/32 (2013.01); C07D 271/06 (2013.01); C07D 277/46 (2013.01); C07D 277/54 (2013.01); C07D 333/36 (2013.01); C07D 409/04 (2013.01); C07D 417/12 (2013.01); C07C 2601/02 (2017.05);
Abstract

Compounds according to Formula I: or a pharmaceutically acceptable salt thereof wherein: Ais NRor CR, with Rbeing H or methyl, with methyl, if present, optionally being substituted with one or more F; the cyclopropyl moiety can be optionally substituted with one or more methyl and one or more F; A-Aare N or CR-CR, respectively, with the proviso that no more than two of the four positions A in A-Acan be simultaneously N; R-Rare independently H, halogen, amino, C(1-3)alkoxy, (di)C(1-3)alkylamino or C(1-6)alkyl; Rand Rare independently H, F, methyl, ethyl, hydroxyl or methoxy or Rand Rtogether is carbonyl, all alkyl groups, if present, optionally being substituted with one or more F; Ris H or C(1-6)alkyl; Ris selected from the group consisting of Formula II, III, IV and V The compounds can be used as inhibitors of RORγ and are useful for the treatment of RORγ mediated diseases.


Find Patent Forward Citations

Loading…